CL2012001321A1 - Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. - Google Patents
Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes.Info
- Publication number
- CL2012001321A1 CL2012001321A1 CL2012001321A CL2012001321A CL2012001321A1 CL 2012001321 A1 CL2012001321 A1 CL 2012001321A1 CL 2012001321 A CL2012001321 A CL 2012001321A CL 2012001321 A CL2012001321 A CL 2012001321A CL 2012001321 A1 CL2012001321 A1 CL 2012001321A1
- Authority
- CL
- Chile
- Prior art keywords
- piperidin
- spiro
- indolin
- indan
- inden
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26518109P | 2009-11-30 | 2009-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012001321A1 true CL2012001321A1 (es) | 2013-11-15 |
Family
ID=43384775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012001321A CL2012001321A1 (es) | 2009-11-30 | 2012-05-23 | Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8822486B2 (es) |
| EP (1) | EP2507228B1 (es) |
| JP (1) | JP5709889B2 (es) |
| KR (1) | KR101410103B1 (es) |
| CN (1) | CN102648195B (es) |
| AR (1) | AR078948A1 (es) |
| AU (1) | AU2010324987B2 (es) |
| BR (1) | BR112012012903A2 (es) |
| CA (1) | CA2781292C (es) |
| CL (1) | CL2012001321A1 (es) |
| CR (1) | CR20120296A (es) |
| DO (1) | DOP2012000139A (es) |
| EA (1) | EA020507B1 (es) |
| EC (1) | ECSP12011930A (es) |
| ES (1) | ES2526568T3 (es) |
| GT (1) | GT201200164A (es) |
| IL (1) | IL219594A0 (es) |
| MA (1) | MA33840B1 (es) |
| MX (1) | MX2012006233A (es) |
| NZ (1) | NZ600203A (es) |
| PE (1) | PE20121474A1 (es) |
| TN (1) | TN2012000248A1 (es) |
| TW (1) | TW201141866A (es) |
| WO (1) | WO2011066183A1 (es) |
| ZA (1) | ZA201203055B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| JP5002077B2 (ja) | 2009-12-25 | 2012-08-15 | 持田製薬株式会社 | 新規３−ヒドロキシ−５−アリールイソチアゾール誘導体 |
| CA2813639A1 (en) | 2010-10-08 | 2012-04-12 | Mochida Pharmaceutical Co. Ltd. | Cyclic amide derivative |
| US8557766B2 (en) | 2011-04-27 | 2013-10-15 | Mochida Pharmaceutical Co., Ltd. | 3-hydroxyisothiazole 1-oxide derivatives |
| WO2012147516A1 (ja) | 2011-04-28 | 2012-11-01 | 持田製薬株式会社 | 環状アミド誘導体 |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| CA2905726C (en) | 2013-03-14 | 2022-05-31 | Janssen Pharmaceutica Nv | Gpr120 agonists for the treatment of type ii diabetes |
| IN2013MU03577A (es) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| WO2019204609A1 (en) | 2018-04-19 | 2019-10-24 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN112399874B (zh) | 2018-07-13 | 2024-03-22 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| WO2021263039A1 (en) | 2020-06-26 | 2021-12-30 | Kallyope, Inc. | Ampk activators |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| US7329673B2 (en) * | 2003-04-04 | 2008-02-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists |
| CA2544602A1 (en) | 2003-11-04 | 2005-05-26 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| WO2005095338A1 (ja) * | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | アルコキシフェニルプロパン酸誘導体 |
| US7960402B2 (en) * | 2004-09-07 | 2011-06-14 | Banyu Pharmaceutical Co., Ltd. | Carbamoyl-substituted spiro derivative |
| MX2009000475A (es) * | 2006-07-19 | 2009-07-10 | Astrazeneca Ab | Nuevos compuestos de espiropiperidina triciclicos, su sintesis y sus usos como moduladores de la actividad de los receptores de quimioquinas. |
| WO2008038692A1 (fr) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
| DE602007010359D1 (de) * | 2006-12-29 | 2010-12-16 | Hoffmann La Roche | Azaspiroderivate |
| WO2008130514A1 (en) * | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| ME02338B (me) | 2007-10-26 | 2013-02-28 | Japan Tobacco Inc | Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe |
| AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 CA CA2781292A patent/CA2781292C/en not_active Expired - Fee Related
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/en active Application Filing
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/en active Active
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active IP Right Cessation
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2012000139A (es) | 2012-08-15 |
| ECSP12011930A (es) | 2012-07-31 |
| CN102648195A (zh) | 2012-08-22 |
| NZ600203A (en) | 2013-09-27 |
| MA33840B1 (fr) | 2012-12-03 |
| CN102648195B (zh) | 2015-01-07 |
| CA2781292C (en) | 2014-04-22 |
| AU2010324987A1 (en) | 2012-07-26 |
| KR101410103B1 (ko) | 2014-06-25 |
| TW201141866A (en) | 2011-12-01 |
| MX2012006233A (es) | 2012-07-03 |
| EA020507B1 (ru) | 2014-11-28 |
| CR20120296A (es) | 2012-07-16 |
| EP2507228A1 (en) | 2012-10-10 |
| JP5709889B2 (ja) | 2015-04-30 |
| US8822486B2 (en) | 2014-09-02 |
| TN2012000248A1 (en) | 2013-12-12 |
| CA2781292A1 (en) | 2011-06-03 |
| ZA201203055B (en) | 2013-09-25 |
| IL219594A0 (en) | 2012-06-28 |
| GT201200164A (es) | 2014-02-27 |
| WO2011066183A1 (en) | 2011-06-03 |
| ES2526568T3 (es) | 2015-01-13 |
| AU2010324987B2 (en) | 2014-01-30 |
| KR20120088770A (ko) | 2012-08-08 |
| EP2507228B1 (en) | 2014-11-05 |
| EA201290416A1 (ru) | 2012-11-30 |
| BR112012012903A2 (pt) | 2017-03-01 |
| JP2013512277A (ja) | 2013-04-11 |
| AR078948A1 (es) | 2011-12-14 |
| US20120220616A1 (en) | 2012-08-30 |
| PE20121474A1 (es) | 2012-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012001321A1 (es) | Compuestos derivados de espiro inden (o indan) - 1,4-piperidin o espiro indolin - 3,4-piperidin, activadores gpr40; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes. | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
| CL2013002939A1 (es) | Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CL2011003350A1 (es) | Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
| CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
| CL2007003033A1 (es) | Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii. | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| CL2012000573A1 (es) | Compuestos derivados de bifenil-pirrolidinil-imidazol; composicion farmaceutica que los comprende; su uso en el tratamiento de una infeccion viral por hcv. | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
| CL2013000727A1 (es) | Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c. | |
| CL2009000173A1 (es) | Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros. | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2007001630A1 (es) | Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
| CL2007000311A1 (es) | Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
| CL2007002121A1 (es) | Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab | |
| CL2013001141A1 (es) | Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c. |